143 results about "Donohue's syndrome" patented technology

The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e.g., topiramate) such that the subject experiences weight loss.

The combination methods of the present invention also are effective against symptoms associated with Syndrome X. The invention also features pharmaceutical compositions and kits for use in the practice of these novel therapies.

The invention belongs to the technical field of medicine, and particularly relates to an amorphous ambroxol hydrochloride compound and a preparation method thereof. The amorphous ambroxol hydrochloride compound has high purity and stability, does not have obvious moisture absorption and weight increase even under the condition of high humidity, ensures that relative substances do not grow, and has higher dissolution rate than crystalline ambroxol hydrochloride. The invention also relates to an application of the amorphous ambroxol hydrochloride compound in preparation of medicine for the treatment of acute and chronic pulmonary diseases with the symptom of ropy sputum and difficult expectoration, phlegm eliminating treatment of acute exacerbation of chronic bronchitis, asthmatic bronchitis and bronchial asthma, prophylactic treatment of lung complication after an operation, and treatment of infant respiratory distress syndrome (IRDS) of premature infants and neonates.

The present invention provides methods, systems, and code for accurately classifying whether a sample from an individual is associated with irritable bowel syndrome (IBS). In particular, the present invention is useful for classifying a sample from an individual as an IBS sample using a statistical algorithm and/or empirical data. The present invention is also useful for ruling out one or more diseases or disorders that present with IBS-like symptoms and ruling in IBS using a combination of statistical algorithms and/or empirical data. Thus, the present invention provides an accurate diagnostic prediction of IBS and prognostic information useful for guiding treatment decisions.

The invention provides a probe set and a reagent kit used for detecting pathopoiesia/susceptibility genes of congenital megacolon and relative syndromes. At most 172 pathopoiesia/susceptibility genes related to diseases can be detected at the same time, and reference can be provided for affected individual molecular genetics diagnosis, mass survey of congenital megacolon high-incidence areas, screening of high-risk affected groups in congenital megacolon family members and corresponding genetic counseling or prenatal intervention.

The invention provides a noninvasive fetus 21, 18 and 13 trisomic syndrome antenatal detection positive quality control product and a preparing method thereof, and belongs to the fetus chromosome aneuploid noninvasive antenatal detection range. The preparing method of the positive quality control product includes the steps that DNAs of abortion groups of fetuses suffering from 21, 18 and 13 trisomic syndromes are broken into DNA fragments with the length ranging 160 bp to 200 bp; the abortion group DNA fragments recycled after breaking are added into mixed plasma in proportion; and the total plasma free DNAs are finally extracted, and the positive quality control products with different concentrations are prepared after attenuation with ultrapure water is carried out. The positive quality control product is a white transparent DNA solution, and has the beneficial effects of being stable, easy to store, convenient and rapid to use, non-toxic and the like; in addition, deviations of detection results of other samples in the same batch can be effectively avoided; and the accuracy and the reliability of the 21, 18 and 13 trisomic syndrome noninvasive antenatal detection are improved.

The invention discloses a method for screening, evaluating and intervening senile syndromes of hospitalized senile patients, which comprises the following steps of: comprehensively screening the senile syndromes of the senile patients; carrying out special assessments including pressure sore risk degree, disability degree, emotional disorder degree, sleep quality, cognitive disorder degree, malnutrition degree, dysphagia degree, defecation and urination, social support, pain, delirium, tumble, sarcopenia, weakness, body diseases and the like; and making individualized intervention suggestions according to the evaluation conclusion. According to the invention, elderly health management is associated with different states of diseases, an elderly syndrome intelligent management method is provided for elderly patients in a targeted manner, and disease hierarchical management and continuous service are realized. The method comprises a complete process of health information collection, disease and function evaluation, intervention opinions and follow-up visits, so that the method can be widely popularized as a special diagnosis and treatment technical method of the elderly medical inpatient department, and can enable the elderly to obtain better standard, effective and homogenized services.

The present invention relates generally to genetic markers for duplication and/or deletion syndromes, such as Wolf-Hirschhorn syndrome (WHS), in particular to copy number variant genetic markers for selecting a patient for therapy for the particular therapy, or predicting the response of a subject to a particular therapy.

The invention provides a method for generating a type II diabetes mellitus and/or Syndrome X model in pigs. A method of the invention comprises partially destructing pancreatic beta-cells in pigs. From these pigs, a pig is preferably selected that comprises a fasting plasma glucose level higher than 6 mmol/L. The invention further provides a pig according to the invention and uses thereof.

The invention discloses the therapeutic and prophylactic administration of leptin to (i) an infant of low birth weight for age; (ii) a nursing mother of an infant, the infant having low birth weight for age; or (iii) a pregnant female predisposed to giving birth to an infant of low birth weight for age; for the prevention or treatment, in later life of the infant, of a metabolic disorder or other condition associated with low birth weight, such as type 2 diabetes, obesity, cardiovascular disease, gestational diabetes, impaired glucose tolerance, insulin resistance, hypertension or syndrome X. It is thought that the beneficial properties of leptin may be due at least in part to an effect on glucocorticoid metabolism, in particular to an increase in type 2 11β-hydroxysteroid dehydrogenase activity.

Long QT Syndrome (LQTS) is a cardiovascular disorder characterized by prolongation of the QT interval on electrocardiogram and presence of syncope, seizures and sudden death. Five genes have been implicated in Romano-Ward syndrome, the autosomal dominant form of LQTS. These genes are KVLQT1, HERG, SCN5A, KCNE1 and KCNE2. Mutations in KVLQT1 and KCNE1 also cause the Jervell and Lange-Nielsen syndrome, a form of LQTS associated with deafness, a phenotypic abnormality inherited in an autosomal recessive fashion. Mutational analyses were used to screen 262 unrelated individuals with LQTS for mutations in the five defined genes. A total of 134 mutations were observed of which eighty were novel.

The present disclosure is directed to methods for i) promoting gut regeneration, ii) promoting gut maturation and/or adaptation, iii) supporting gut barrier resistance and/or iv) protecting gut barrier function in a pediatric subject comprising administering to the pediatric subject a composition comprising an effective amount of a soluble mediator preparation derived from a late-exponential growth phase of a probiotic batch-cultivation process, such as Lactobacillus rhamnosus GG (LGG). The present methods advantageously provide the gut-protection benefits of LGG soluble mediators without introducing live bacterial culture to individuals with impaired gut barrier function. In some embodiments, the pediatric subject has impaired gut barrier function and/or short bowel syndrome. The present disclosure in other embodiments, directed methods for reducing visceral pain in a pediatric subject comprising administering to the pediatric subject a composition comprising an effective amount of a soluble mediator preparation from a late-exponential growth phase of a probiotic batch-cultivation process, such as LGG.

The invention discloses a kit for non-invasive prenatal screening for trisomy syndrome and an application thereof. The kit of the present invention includes a primer pair and a probe for prenatal screening of trisomy 13 syndrome, a primer pair for prenatal screening of trisomy 18 syndrome, and a primer pair and a probe for prenatal screening of trisomy 21 syndrome. The invention also discloses a non-invasive prenatal screening method for trisomy syndrome. Compared with a second-generation sequencing method, the screening method has the advantages of low cost, short detection period, high detection sensitivity, convenience and absolute quantification.

A composition and method of treatment of neuromuscular, neuromuscular degenerative, neurodegenerative, autoimmune, developmental, traumatic, hearing loss related, and/or metabolic diseases, including spinal muscular atrophy (SMA) syndrome (SMA1, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome. The composition is selected from the group consisting of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP, bipartite 2,3-dinitrophenol, 2,4-dinitrophenol, 2,5-dinitrophenol, 2,6-dinitrophenol, 3,4-dinitrophenol, or 3,5-dinitrophenol (2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP) prodrugs; Gemini prodrugs, bioprecursor molecules, and combinations thereof. A dose of the composition for treatment of neurodegenerative diseases may be from about 0.01 mg/kg of body weight to about 50 mg/kg of body weight of the patient in need of treatment. A dose of the composition for treatment of metabolic diseases may be from about 1 mg/70 kg of body weight to about 100 mg/70 kg of body weight of the patient in need of treatment, and a maximum dose per day is about 200 mg/70 kg of body weight of the patient in need of treatment.

The invention relates to the technical field of medical information processing, aims to solve the problems of high human resource consumption and no pertinence in the existing post-ICU syndrome intervention guidance process, and provides a follow-up visit method and system for post-ICU syndrome, and the main scheme comprises the following steps: obtaining patient basic information of a patient during an ICU period, wherein the basic information of the patient at least comprises clinical indexes related to the post-ICU syndrome; according to the basic information of the patient and in combination with a post-ICU syndrome risk knowledge base, calculating the risk type and grade of the post-ICU syndrome of the corresponding patient, and according to the risk and grade, generating a corresponding medical staff nursing plan, a patient movement plan, a doctor follow-up plan and a patient self-measurement table. According to the invention, the investment of human resources is reduced, the pertinence of rehabilitation guidance is improved, and the method and system are suitable for follow-up visit of post-ICU syndromes.

An orifice probe, particularly for detecting if a patient has or has a risk of having cauda equina syndrome and a method for using same, the probe having a body for insertion into the anus of a patient, a sensing device for measuring at least one of the rectal tone and perianal or rectal sensation, and an output device for yielding at least one of the measurement of the rectal tone of the patient and whether the patient has perianal or rectal sensation.

A method and system for the assessment of the risk of development of disseminated intravascular coagulation (DIC), in patients showing systemic inflammatory response syndrome (SIRS) or sepsis is disclosed. Specifically, the invention provides a method for early DIC assessment and preventive treatment planning, which has the potential for significantly decreasing mortality rate as well as the rate of DIC related sequelae in the SIRS/sepsis patient population and thereby improving quality of life. The risk assessment method is based on features of vital signs and/or biomarker measurements, and provides solutions for assessing the risk of DIC development 24 hours in advance or within 72 hours after ICU admittance.

The invention relates to application of lactobacillus reuteri in preparation of products for preventing or treating developmental disorder diseases. The preservation number of the lactobacillus reuteri is CGMCC (China General Microbiological Culture Collection Center) No. 21577. The lactobacillus reuteri can improve the composition of intestinal flora of patients with developmental disorder diseases such as the Prallard-Willard syndrome and the autism, and improve the disorder of the intestinal flora. The bacteria can prevent obesity or promote weight loss caused by diet, can improve brain development of patients with developmental disorder diseases such as the Prallard-Willie syndrome and autism, can improve social contact disorders and communication disorders of the patients, and can improve fine exercise ability of the patients.

The invention belongs to the technical field of medical information and discloses an information acquisition system for a joint marker for diagnosing PCOS (polycystic ovarian syndrome). The information acquisition system for the joint marker for diagnosing the PCOS comprises an excessive androgen measurement module, a serum extraction module, a central control module, a joint marker testing module, a treatment module, a data storage module and a display module. A detection kit can realize high-sensitivity and efficient detection and has the characteristics of low detection cost and good repeatability. Meanwhile, pharmaceutical composition provided by the treatment module and used for the excessive androgen type PCOS comprises medicinal materials including herba epimedii, fritillaria, fructus psoraleae, antler slices, hippocampus, tortoise plastron and the like, does not contain radix et rhizoma rhei or radix angelicae sinensis, notably reduces the androgen level of a patient, improvesgrowth of ovarian follicle and increases the ovulation rate and the pregnancy rate of the patient in the child-bearing period after being taken for a period of time.